- They are planning to vote on Dec 29 to increase the AS to 1 billion shares
- Reason for AS increase - "As a general matter, the Board of Directors does not believe the currently available number of unissued shares of Common Stock is an adequate number of shares to assure that there will be sufficient shares available for issuance in connection with possible future acquisitions, equity and equity-based financings, possible future awards under employee benefit plans, stock dividends, stock splits, and other corporate purposes." - Insiders and 5% stakeholders own around 168 million shares of common stock
Company is targeting a niche market with products ready to sell and an experienced management team who own 90 million shares (skin in the game). See form 4 & 3’s
“Eqova's products are created using full spectrum hemp oil and other ingredients to achieve standardized dosing. These formulations combine the scientifically validated, powerful benefits of cannabinoids in standardized products, which are then distributed to patients under the care of licensed health practitioners. All Eqova products are carefully researched and go through rigorous third-party testing before and after marketing, providing clinical-grade products made in cGMP Compliant Labs located in the United States.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.